Oncology news & research | Hospital Healthcare Europe

This website is intended for healthcare professionals only.

Oncology

Latest developments in intravascular robotics

A novel therapy for high-grade glioma

Managing chemotherapy extravasations in practice

AbbVie announces The Lancet Oncology publication of Phase II data for Venetoclax

AbbVie announces The Lancet Oncology publication of Phase II data for Venetoclax

Urine FISH for detection of urothelial cancer

MALDI-MSI: a powerful tool in cancer research

Treatment of peritoneal surface malignancies

ESMO CPGs for primary breast cancer

The management of cutaneous melanoma

SMC says ‘yes’ to treatment for advanced cervical cancer

SMC says ‘yes’ to treatment for advanced cervical cancer

New European policy recommendations on cytotoxic drugs

New European policy recommendations on cytotoxic drugs

Patients with advanced mCRC have a new treatment option as LONSURF® receives EU approval

Patients with advanced mCRC have a new treatment option as LONSURF® receives EU approval

EADV launches Global Call to Action to protect outdoor workers from skin cancer caused by the sun

EADV launches Global Call to Action to protect outdoor workers from skin cancer caused by the sun

Selvita files IND application for its novel, dual PIM/FLT3 inhibitor in AML

Selvita files IND application for its novel, dual PIM/FLT3 inhibitor in AML

Kymab and Heptares enter strategic collaboration to develop novel antibody therapeutics

Kymab and Heptares enter strategic collaboration to develop novel antibody therapeutics

Merck and Sysmex Inostics receive CE Mark approval for liquid biopsy test for colorectal cancer

Merck and Sysmex Inostics receive CE Mark approval for liquid biopsy test for colorectal cancer

CHMP issues a positive opinion on Janssen’s single-agent Darzalex® (daratumumab)

CHMP issues a positive opinion on Janssen’s single-agent Darzalex® (daratumumab)

Survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone

Survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone

x